Cargando…
In Vitro and In Vivo Anticancer Activity of Gimatecan against Hepatocellular Carcinoma
OBJECTIVE: Gimatecan is a new camptothecin (CPT) analogue that inhibits tumor growth by targeting DNA topoisomerase I (TOP I) and introducing strong and persistent DNA cleavage. Anti-tumor activity has been demonstrated with a wide range of solid tumors in previous preclinical and clinical studies....
Autores principales: | Zhao, Youna, Lau, Lit-Fui, Dai, Xiangrong, Li, Benjamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454685/ https://www.ncbi.nlm.nih.gov/pubmed/28030910 http://dx.doi.org/10.22034/APJCP.2016.17.11.4853 |
Ejemplares similares
-
Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways
por: Chen, Zuhua, et al.
Publicado: (2017) -
A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo
por: Zou, Jianling, et al.
Publicado: (2018) -
TPGS-1000 exhibits potent anticancer activity for hepatocellular carcinoma in vitro and in vivo
por: Chen, Yidan, et al.
Publicado: (2020) -
Mild Hyperthermia Responsive Liposomes for Enhanced In Vitro and In Vivo Anticancer Efficacy of Doxorubicin against Hepatocellular Carcinoma
por: Rahim, Muhammad Abdur, et al.
Publicado: (2021) -
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
por: Pecorelli, S., et al.
Publicado: (2010)